top of page
Thechnology & Pre-clinical Recearch
Technology:
ShortCut™ Device
ShortCut
Unmet Needs in Current TAVR World
01
02
Degenerated valves that require reintervention present a risk of coronary obstruction and coronary access impairment
TAVI in native valves present a risk of coronary impairment in a select group of patients
ShortCut™ - First dedicated leaflet splitting device
Indicated to treat patients at risk of coronary obstruction undergoing valve-in-valve TAVR
Innovative Design
Allows for safe, simple splitting of single or dual leaflets using same device
Intuitive Control
Responsive system allows for precise positioning and leaflet splitting
Efficient Procedure
Maintain regular TAVR workflow with short procedural times
The ShortCut™ Procedure
Play Video
ShortCut™ is a medical device cleared by the U.S. Food and Drug Administration for splitting bioprosthetic valve leaflets for patients at risk for coronary obstruction. For more information, visit www.pi-cardia.net
bottom of page